Cleared Traditional

K163563 - VITEK 2 AST-GN Gentamicin (<=1 – >=16 µg/mL) (FDA 510(k) Clearance)

Mar 2017
Decision
84d
Days
Class 2
Risk

K163563 is an FDA 510(k) clearance for the VITEK 2 AST-GN Gentamicin (<=1 – >=16 µg/mL). This device is classified as a System, Test, Automated, Antimicrobial Susceptibility, Short Incubation (Class II - Special Controls, product code LON).

Submitted by bioMerieux, Inc. (Hazelwood, US). The FDA issued a Cleared decision on March 13, 2017, 84 days after receiving the submission on December 19, 2016.

This device falls under the Microbiology FDA review panel. Regulated under 21 CFR 866.1645.

Submission Details

510(k) Number K163563 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received December 19, 2016
Decision Date March 13, 2017
Days to Decision 84 days
Submission Type Traditional
Review Panel Microbiology (MI)
Summary Summary PDF

Device Classification

Product Code LON — System, Test, Automated, Antimicrobial Susceptibility, Short Incubation
Device Class Class II - Special Controls
CFR Regulation 21 CFR 866.1645

Similar Devices — LON System, Test, Automated, Antimicrobial Susceptibility, Short Incubation

All 25
VITEK 2 AST-Gram Negative Cefazolin (=<1-=>32 µg/mL)
K251579 · bioMerieux, Inc. · Aug 2025
BD Phoenix Automated Microbiology System - GN Eravacycline (0.125-2 µg/mL)
K251713 · Becton, Dickinson and Company · Aug 2025
BD Phoenix™ Automated Microbiology System - GN Imipenem-relebactam (0.0625/4 - 16/4 µg/mL)
K250447 · Becton, Dickinson and Company · May 2025
VITEK COMPACT PRO
K234012 · bioMerieux, Inc. · Mar 2025
BD Phoenix™ Automated Microbiology System
K250344 · Becton, Dickinson and Company · Mar 2025
BD Phoenix™ Automated Microbiology System - GN Ciprofloxacin (0.0156–4 µg/mL)
K233986 · Becton, Dickinson and Company · Mar 2024